|
Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Business Market Research
Energy Market Research
Financial Market Research
Pharmaceutical Market Research
Telecoms Market Research
|
Home > Market Research > Prescription Medicines > The Pharmaceutical Market: Czech Republic
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
The Czech Republic was one of the larger countries to join the EU in May 2004 and it has the third largest pharmaceutical market in the region. Local production of generics is strong, and was enhanced in 2003 by the merger of the leading Czech manufacturer, Leciva, with its Slovak counterpart, Slovakofarma, to form Zentiva. There is little branded manufacturing in the Czech Republic. The Czech Republic is easily reached from other EU countries such as Germany or Austria, and the market is increasingly dominated by imported products.
The country has a history of high drug consumption, a legacy of many years of reliance on cheap generics. In January 2008, the government introduced new fees for prescriptions and visits to the doctor that could result in reduced pharmaceutical sales. The opposition argues that the fees violate the law which guarantees medical care for every citizen. People aged under 18 years are now exempt from the fees.
Healthcare funding is largely public, through health insurance. Provision of care is also largely public; the Czech Republic has yet to develop a substantial private sector. Private spending only accounts for around 12.1% of the total in 2010. One of the reasons for the new fees introduced in 2008 was to increase funding for the healthcare system.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data
Top of Page
Table of Contents
EXECUTIVE SUMMARY 1
Introduction 2
Pharmaceutical Market Analysis . 3
Size . 3
Market Structure . 3
Generics Sector 5
Projections & Outlook . 5
Imports 9
Parallel Imports . 11
Domestic Manufacturing . 11
Domestic Production . 11
GMP compliance . 12
Trade Associations 16
Local Manufacturers 17
Farmak 17
Glenmark Pharmaceuticals (Medicamenta) . 17
ICN Czech Republic (VUAB) 17
IVAX CR 17
Pliva-Lachema . 18
Spofa . 18
Zentiva . 18
Financial Results . 19
Exports 20
Pharmaceutical Regulatory Analysis 22
Pharmaceutical Regulation . 22
New EU Rules . 22
Pharmaceutical Registration/Drug Approval Process . 23
Clinical trials 23
Post marketing surveillance 23
Advertising 24
Pricing & Reimbursement . 24
Pricing 24
Reimbursement . 25
Intellectual Property 25
Pharmaceutical Distribution 26
Wholesaling 26
Retailing 26
CZECH REPUBLIC PHARMA OUTLOOK
Pharma Outlook espicom BUSINESS INTELLIGENCE
ii Quarter I 2010
Healthcare Analysis 27
Demographics . 27
Population . 27
Birth Rate . 28
Death Rate 28
Infant Mortality . 28
Life Expectancy at Birth . 28
Public Health . 28
Causes of Death 28
Incidence of Communicable Diseases . 28
Incidence of Non-communicable Diseases 28
Diabetes 29
HIV/AIDS . 29
Healthcare System 29
Health Expenditure . 30
Healthcare Infrastructure 31
Inpatient Analysis 32
Healthcare Personnel . 32
DIRECTORY 33
Government Organisations . 33
Trade Associations . 33
Methodology & Sources . 34
PHARMA OUTLOOK CZECH REPUBLIC
Pharma Outlook espicom BUSINESS INTELLIGENCE
Quarter I 2010 iii
List of Tables
Summary of Key Data Projections, 2010-2015 . 2
Summary of the Czech Pharmaceutical Market, 2010 . 3
Distributed Medicinal Products, 1995-2006 3
Distributed Medicinal Products by ATC, 2006 4
Market Projections, 2010-2015 . 5
SWOT Analysis of the Czech Pharmaceutical Market, 2010 . 6
Espicom Analysis of the Czech Health Sector, 2010 . 7
Imports of Pharmaceuticals by Category, 2003-2007 (US$000s) 9
Import Trends, 2006-2007 (US$000s) 9
Leading Suppliers of Raw Materials, 2007 (US$000s) . 9
Leading Suppliers of Antisera & Vaccines, 2007 (US$000s) . 10
Leading Suppliers of Medicaments, 2007 (US$000s) 10
API Manufacturers with GMP Certificates, January 2009 12
Registered Pharmaceutical Manufacturers, January 2009 12
AIFP Members, 2009 . 16
CAFF Members, 2009 16
Zentiva: Top Brands, 2007 (CZK millions) 19
Zentiva Financial Results, 2000-2008 19
Pharmaceutical Sales by Region, 2006-2007 (CZK millions) 20
Exports of Pharmaceuticals, 2003-2007 (US$000s) . 21
Export Trends, 2006-2007 (US$000s) 21
Leading Destinations, 2007 (US$000s) . 21
SUKL Drug Registration Activity, 2000-2007 23
Pharmacies, 1999-2006 . 26
Summary of Demographic Data, 2007 & 2010 27
Projected Population, 2010-2015 . 27
Healthcare Expenditure, 2007 30
Projected Health Expenditure, 2010-2015 . 30
Hospitals & Beds, 2007 31
Hospital Activity Trends, 1998-2007 32
Projected Number of Physicians, 2010-2015 32
CZECH REPUBLIC PHARMA OUTLOOK
Pharma Outlook espicom BUSINESS INTELLIGENCE
iv Quarter I 2010
List of Charts
Distributed Medicinal Products by ATC, 2006 (CZK billion) . 4
Radar Graph of the Czech Healthcare System . 8
For full details, please email keithw@cmsinfo.com
Top of Page
Buy now!
Top of Page
|
|
